Efficacy of recombinant human endostatin combined with TP regimen on patients with advanced EGFR wild type squamous cell lung carcinoma
10.3760/cma.j.issn.1673-422X.2017.10.006
- VernacularTitle:重组人血管内皮抑制素联合TP方案在晚期EGFR野生型肺鳞状细胞癌患者的疗效观察
- Author:
Wei WANG
1
;
Biyong REN
Author Information
1. 404000,重庆三峡中心医院肿瘤呼吸病区
- Keywords:
Neoplasms,squamous cell;
Lung neoplasms;
Angiostatins;
Cisplatin;
Paclitaxel
- From:
Journal of International Oncology
2017;44(10):745-748
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy of recombinant human endostatin combined with TP(paclitaxel + cisplatin) in the treatment of advanced epidermal growth factor receptor (EGFR) squamous cell lung carcinoma.Methods From January 2012 to February 2015,100 patients with squamous cell lung carcinoma in Chongqing Three Gorges Central Hospital for medical treatment were selected as the subjects.According to different treatment methods,they were divided into single group (n =50) and combined group (n =50).The single group used the TP protocol and the combined group was treated with recombinant human endostatin on the basis of the TP protocol.The therapeutic effect was evaluated according to the Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1).The short-term effects,long-term effects,adverse reactions,hospitalization time and expenses were also analyzed.Results The objective effective rate in the combined group [52.0％ (26/50)] was significantly higher than that in the single group [16.0％ (8/50)],with a significant difference (x2 =14.429,P =0.007).The disease control rate in the combined group was higher than that in the single group (80.0％ vs.52.0％),with a significant difference (x2 =8.734,P =0.009).Compared with the patients in the single group,the median progression free survival (8.4 months vs.6.3 months)and overall survival (17.7 months vs.11.5 months) in the combined group were prolonged obviously,with significant differences (x2 =5.390,P =0.025;x2 =3.993,P =0.035).The incidence rates of adverse reactions in single group were basically the same compared with the combined group,and the difference was not statistically significant (all P ＞0.05).Compared with the single group,the hospitalization time in combined group was longer [(23.5 ± 2.8) weeks vs.(18.2 ± 3.5) weeks],and the expenses in combined group was higher [(112 453.9 ± 994.9) yuan vs.(87 821.4 ± 943.2) yuan],with significant differences (t =8.361,P ＜0.001;t =127.051,P ＜0.001).But the satisfaction of patients in combined group was significantly higher than that in single group (88.0％ vs.64.0％,x2 =4.210,P =0.017).Conclusion Recombinant human endostatin combined with TP regimen is effective in the treatment of advanced EGFR wild-type squamous cell lung carcinoma,and has a low incidence of adverse reactions.It is suitable for clinical application.
